The purpose of the study is to determine whether taking ticagrelor alone is as safe and effective as the standard two‑medicine regimen in preventing serious bleeding and major heart problems over one year. Participants are randomly assigned to one of the two groups and take the assigned tablets daily for twelve months, with routine check‑ups scheduled throughout the year to monitor health and any side effects.

Researchers will look at two main outcomes: first, any bleeding events classified by the Bleeding Academic Research Consortium as type 2, 3, or 5, which represent moderate to severe bleeding; and second, a combined measure that includes death from any cause, another heart attack, stroke, or the need for a procedure to open blocked heart arteries (coronary revascularization). Information on these events will be collected during the scheduled visits and recorded for analysis.

Participants will receive a series of injections over a period of several weeks, with regular visits to the clinic where doctors will ask about eye symptoms, quality of life, and ability to perform daily activities. Simple questionnaires will be used to measure changes in eye muscle strength and overall well‑being. The study will also monitor any side effects that may occur during the treatment period.

Participants are randomly assigned, meaning the decision is made by chance, to receive either the lidocaine or the saline, and the trial is double‑blind so neither the care team nor the patients know which one is given. After the operation, pain is measured using a simple number scale from 0 (no pain) to 10 (worst pain) at several time points up to six months, along with questionnaires about daily activities and overall well‑being. The study follows each person for about half a year to see how the treatment affects long‑term pain and recovery.

The purpose of the study is to compare how well BNT324 works against docetaxel in slowing disease progression and extending survival. Participants are randomly assigned to one of the two groups and receive the assigned medication in cycles, typically every three weeks, with treatment continuing until the disease worsens, side effects become too severe, or the planned treatment period ends.

During the trial, patients undergo regular imaging scans to check for changes in tumor size, blood tests to monitor prostate‑specific antigen levels, and assessments of pain and overall health. The study records how long the cancer remains stable, the time until death from any cause, and any side effects experienced.

The purpose of the trial is to evaluate the safety and clinical activity of the drug and to determine the appropriate dose for later studies. Participants will receive a series of injections over several weeks while doctors monitor them closely for any signs of dose limiting toxicities, adverse events or serious adverse events. Routine visits will include blood work, checks of vital signs such as blood pressure and heart rate, and an electrocardiogram (ECG) to record the heart’s electrical activity.

Additional evaluations will look at how well the cancer responds, measured by the Overall Response Rate (ORR), and will also assess how the drug behaves in the body, including its Maximum concentration (Cmax), the time it takes to reach that level (Time to Cmax (Tmax)), and the total exposure over time (Area under the curve (AUC)). These assessments help researchers understand both the effectiveness and the safety profile of the treatment.

Two medicines are being compared: an intravenous infusion of rituximab, which is given through a vein to target immune cells, and oral tablets of azathioprine, a pill that also reduces immune activity. Participants will receive the assigned medication over a period of up to two years while doctors monitor their health.

During the study, participants will have regular clinic visits, blood tests, and brain scans using MRI with contrast dye to check for any new or worsening signs of disease. The study will track how long participants stay free of relapse and record any side effects or changes in medication over the 24‑month follow‑up.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of the study is to determine how effectively this drug combination can delay the need for additional cancer therapy. Participants receive the study tablets for up to two years while attending regular check‑ups where doctors monitor health, side effects, and any changes in the cancer. Safety is closely watched through routine tests and reporting of any adverse effects.

The purpose is to compare a short 3‑day treatment course with the usual 7‑day course. After enrollment, patients are randomly assigned to receive antibiotics for either three or seven days while staying in the hospital. Throughout the treatment period and during follow‑up visits, medical staff monitor body temperature, signs of infection and any worsening of health, such as low blood pressure, breathing difficulty, kidney or liver problems, and rare complications like septic shock. The study records how quickly patients recover, any side effects, and the length of hospital stay.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to determine if the eye drops allow the interval between injections to be extended. Vision will be measured with a standardized eye chart called the ETDRS chart, which provides a precise reading of visual sharpness. The health of the retina will be monitored using OCT, a non‑invasive scan that creates detailed cross‑section images of the back of the eye. Safety checks will include measuring the eye’s internal pressure (IntraOcular Pressure), assessing tear film stability with the Tear Break-Up Time test, and rating any irritation on a Visual Analog Scale, a simple line where participants indicate how uncomfortable they feel.

Participants will use the assigned eye drops daily for about nine months and will attend regular clinic visits for eye examinations and possible adjustment of injection timing. The study is double‑blind, meaning neither the participants nor the doctors know which drops are being used, and data on injection frequency, visual acuity, retinal thickness, and safety outcomes will be collected at the end of the treatment period.

Participants will take the assigned medication for about three months. Their heart rhythm will be recorded using a portable device called a Holter-ECG, which continuously monitors the heart’s electrical activity for a week at the start of the study and again after three months. In addition, participants will answer simple questionnaires that measure overall well‑being, including the EQ-5D visual scale and the SF-12 health survey, to see how the treatment impacts daily life.

Throughout the study, any side effects such as fatigue, dizziness, low blood pressure, or more serious heart problems will be recorded. The need for additional procedures, such as a catheter-based technique to destroy the source of the extra beats, will also be noted. The overall goal is to find the safer and more effective option for managing these premature heartbeats.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.

The purpose of the study is to determine how well this test can serve as a biomarker for detecting the SDHx mutation by measuring a unique pattern of sugar metabolism in the blood, and to compare the results with standard genetic testing. A biomarker is a measurable sign that can indicate the presence of a disease or a genetic change.

Participants will receive the sugar infusion, have blood drawn at several time points, and then undergo the planned tumor removal surgery. The blood samples will be examined for the specific metabolic pattern, and the findings will be compared with tumor size seen on imaging and with the tissue analysis after surgery. The study follows each person from the infusion through the surgical procedure and a short follow‑up period.

Participants will receive one tablet each day for about nine months. Throughout the study they will visit the clinic regularly, where health care staff will collect a urine sample, usually the first morning urine, and perform a simple test that compares the protein level to a normal waste product to see how much protein is present. Blood samples will also be taken to understand how the body absorbs and clears the medication. Doctors will monitor safety by checking for any side effects, routine lab results, and vital signs during the visits.